The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high ...

Please read this leaflet carefully before you start using TRELEGY ELLIPTA. This leaflet answers some common questions about TRELEGY ELLIPTA. It does not contain all the available information.

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma ... with GSK’s double therapy Relvar/Breo (fluticasone furoate+umeclidinium ...

However the company has seen numerous recent setbacks to its respiratory franchise, and has to convince investors that new treatments such as Breo, Anoro and Incruse will help it sustain its ...

73 x 91 cm. (28.7 x 35.8 in.) ...

Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through your mouth so they can directly reach your lungs. If your healthcare ...